Perimeter Solutions heads into the close of its May 7 investor day having already dropped 9% on earnings day — a stock that beat on both revenue and EPS but still couldn't hold its gains.
The stock fell 9.2% on Wednesday after reporting Q1 adjusted EPS of $0.06 against a $0.02 estimate, with revenue of $125.1M beating the $121.8M consensus. That gap between a clean beat and a sharp selloff mirrors the February print almost exactly: after Q4 2025 results, PRM fell 11% on the day and extended losses to roughly 7.7% over the following five trading sessions. The pattern is consistent — good numbers, worse reaction. The Q1 2026 print continues that sequence.
One headline from Wednesday's earnings call added a new dimension to the setup. Management outlined a DLA foams deal worth up to $500M in total value, with approximately $50M of incremental revenue expected to hit in 2027. That is a meaningful contract for a company trading around an $860M revenue run rate. Markets appear to have treated it as a longer-dated catalyst rather than an immediate earnings driver — potentially explaining why a beat was still met with selling.
The institutional picture suggests conviction among active holders, not just passive indexers. Co-Chairman William Thorndike holds 5.2% of the company after reporting a large position change in early April, while CEO Haitham Khouri's stake grew by 1.6 million shares to 2% of shares outstanding — also reported as of April 7. Against that, March insider activity ran the other way: Thorndike sold roughly 650,000 shares across six transactions between March 4 and March 11, realising proceeds north of $15M at prices in the $23–$24 range. Those sales came below current levels, making them somewhat dated as a sentiment read.
Short positioning is not what is driving the story here. Short Interest is low at 2.2% of the free float, with the ORTEX short score a modest 32.9 out of 100. Availability in the lending market is ample. Borrowing costs have nudged higher — up roughly 16% on the week to 0.57% — but remain negligible in absolute terms. Options positioning sits slightly below its 20-day average, with the put/call ratio at 0.34 versus a mean of 0.36, suggesting no elevated hedging demand.
Analyst coverage is thin, with UBS as the primary visible voice. UBS upgraded PRM to Buy and raised its target to $30 on March 31 — a move that preceded the stock's subsequent rally from the low $20s to a peak above $30 before Wednesday's reversal. With the stock now at $27.41, UBS's target sits modestly above current levels. The DLA foams deal gives bulls a forward revenue story to point to; the recurring sell-on-results pattern and the still-elevated net debt load of roughly $1B give bears reasons to stay cautious.
The Q1 beat is now in the market. What the next sessions test is whether the DLA foams catalyst is enough to reverse the stock's established habit of fading after a good print.
See the live data behind this article on ORTEX.
Open PRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
